Braxia Scientific Corp (OP: BRAXF )
0.0199 +0.0004 (+2.05%) Streaming Delayed Price Updated: 3:58 PM EDT, Jun 9, 2023 Add to My Watchlist
All News about Braxia Scientific Corp
BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
June 09, 2023
Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting...
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
February 21, 2023
Irwin Naturals Inc. (OTCQB: IWINF) (CSE:IWIN) (FRA:97X) has successfully completed the acquisition of Serenity Health, LLC, a ketamine clinic in Louisville, KY. The agreement with Serenity was...
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
December 01, 2022
Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and...
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
September 13, 2022
The season for psychedelics conferences is right around the corner. From very large and well-known events to small meets, this year’s remaining months are loaded with on-site and virtual discussions...
Braxia Scientific Corp. (OTCPK:BRAXF) (CSE:RAX) (FWB:4960) recorded revenue of $1.49 million for the fiscal 2022 year ended March 31, 2022 compared with revenue of $1.008 million for the year ended...
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following